1. Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registry
- Author
-
Jean-Yves Le Heuzey, A. John Camm, Marita Knudsen Pope, Jørn Dalsgaard Nielsen, Garfield-Af Investigators, K.E. Juhani Airaksinen, Dan Atar, Torstein Hole, Jean-Pierre Bassand, Janina Stępińska, Pekka Raatikainen, Gloria Kayani, Milita Crisby, Saverio Virdone, Karen S. Pieper, Jan Steffel, Arne Svilaas, Ulrik Hintze, Kardiologian yksikkö, HUS Heart and Lung Center, Helsinki University Hospital Area, Tampere University, and TAYS Heart Centre
- Subjects
Male ,medicine.medical_specialty ,Embolism ,030204 cardiovascular system & hematology ,Scandinavian and Nordic Countries ,3121 Internal medicine ,antithrombotic treatment ,Risk profile ,Drug Prescriptions ,03 medical and health sciences ,Antithrombotic treatment ,0302 clinical medicine ,Fibrinolytic Agents ,Risk Factors ,Internal medicine ,Cause of Death ,medicine ,Humans ,030212 general & internal medicine ,Prospective Studies ,Registries ,Stroke ,Aged ,Aged, 80 and over ,business.industry ,Anticoagulants ,Systemic embolism ,Atrial fibrillation ,General Medicine ,Middle Aged ,medicine.disease ,3. Good health ,Clinical trial ,Europe ,Treatment Outcome ,Nordic countries ,Baseline characteristics ,3121 General medicine, internal medicine and other clinical medicine ,population characteristics ,Drug Therapy, Combination ,Female ,stroke prevention ,business ,Cardiology & Cardiovascular Disorders ,Major bleeding ,Platelet Aggregation Inhibitors ,Research Article - Abstract
Aims The objective was to evaluate the clinical characteristics, management and two-year outcomes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in Nordic countries. Methods We examined the baseline characteristics, antithrombotic treatment, and two-year clinical outcomes of patients from four Nordic countries. Results A total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in combination with antiplatelet (AP), was higher in Nordic patients in all CHA2DS2-VASc categories: 0–1 (72.8% vs 60.3%), 2–3 (78.7% vs 72.9%) and ≥4 (79.2% vs 74.1%). In Nordic patients, NOAC ± AP was more frequently prescribed (32.0% vs 27.7%) and AP monotherapy was less often prescribed (10.4% vs 18.2%) when compared with Non-Nordic European patients. The rates (per 100 patient years) of all-cause mortality and non-haemorrhagic stroke/systemic embolism (SE) were similar in Nordic and Non-Nordic European patients [3.63 (3.11–4.23) vs 4.08 (3.91–4.26), p value = .147] and [0.98 (0.73–1.32) vs 1.02 (0.93–1.11), p value = .819], while major bleeding was significantly higher [1.66 (1.32–2.09) vs 1.01 (0.93–1.10), p value
- Published
- 2021